Takao Hidemasa, Nojo Takeshi
Department of Radiology, Showa General Hospital, and Department of Radiology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Radiology. 2007 Sep;244(3):755-66. doi: 10.1148/radiol.2443061278. Epub 2007 Jul 24.
To prospectively perform a decision and cost-effectiveness analysis of surgical and endovascular treatments of unruptured intracranial aneurysms, with incorporation of the results of the prospective International Study of Unruptured Intracranial Aneurysms.
With use of a Markov model, a decision and cost-effectiveness analysis was performed for comparison of surgical or endovascular treatment with no treatment. Twelve clinical scenarios were defined on the basis of aneurysm size and location. Probabilistic sensitivity analyses were performed for 50- and 40-year-old patient cohorts. Treatment was considered to be cost-effective at an incremental cost-effectiveness ratio less than $100,000 per quality-adjusted life-year.
In 50-year-old patients, no treatment was the most cost-effective strategy for aneurysms located in the cavernous carotid artery. For aneurysms smaller than 7 mm located in the anterior circulation, no treatment was the most cost-effective strategy. Endovascular treatment was the most cost-effective option for 7-24-mm aneurysms, whereas surgical treatment was the most cost-effective option for aneurysms 25 mm or larger. For aneurysms smaller than 7 mm or 25 mm or larger located in the posterior circulation, no treatment was the most cost-effective strategy. Surgical treatment was the most cost-effective option for 7-12-mm aneurysms, whereas endovascular treatment was the most cost-effective option for 13-24-mm aneurysms.
For 50-year-old patients, treatment of aneurysms that are small (<7 mm), that are located in the cavernous carotid artery, or that are large (>or=25 mm) and located in the posterior circulation is ineffective or not cost-effective.
前瞻性地对未破裂颅内动脉瘤的手术和血管内治疗进行决策及成本效益分析,并纳入前瞻性国际未破裂颅内动脉瘤研究的结果。
使用马尔可夫模型进行决策及成本效益分析,以比较手术或血管内治疗与不治疗的效果。根据动脉瘤的大小和位置定义了12种临床情况。对50岁和40岁的患者队列进行概率敏感性分析。当增量成本效益比低于每质量调整生命年10万美元时,治疗被认为具有成本效益。
在50岁的患者中,对于位于海绵窦段颈内动脉的动脉瘤,不治疗是最具成本效益的策略。对于位于前循环且小于7mm的动脉瘤,不治疗是最具成本效益的策略。血管内治疗是7 - 24mm动脉瘤最具成本效益的选择,而手术治疗是25mm或更大动脉瘤最具成本效益的选择。对于位于后循环且小于7mm或25mm或更大的动脉瘤,不治疗是最具成本效益的策略。手术治疗是7 - 12mm动脉瘤最具成本效益的选择,而血管内治疗是13 - 24mm动脉瘤最具成本效益的选择。
对于50岁的患者,治疗小(<7mm)、位于海绵窦段颈内动脉、大(≥25mm)且位于后循环的动脉瘤是无效的或不具有成本效益的。